Core Insights - Certara, Inc. reported strong financial results for Q4 2024, with total revenue of 100.4million,reflectingayear−over−yeargrowthof14415 million and 425million,withadjustedEBITDAmarginsintherangeof30−32100.4 million, up from 88.0millioninQ42023,markinga1442.3 million, a 26% increase from 33.6millioninQ42023,drivenbygrowthinbiosimulationsoftware[5][8]−Servicesrevenuewas58.1 million, up 7% from 54.4millioninQ42023,primarilyduetodemandforbiosimulationservices[5][8]BookingsandGrowth−TotalbookingsforQ42024were144.5 million, representing a 22% year-over-year growth [6][8] - Software bookings increased by 38% to 59.7million,attributedtostrongperformanceinCertara′scorebiosimulationsoftware[6][8]−Servicesbookingsgrewby1284.8 million, driven by increased demand for biosimulation and regulatory services [7][8] Profitability Metrics - Net income for Q4 2024 was 6.6million,comparedtoanetlossof12.5 million in Q4 2023 [12][11] - Adjusted EBITDA for Q4 2024 was 33.5million,a1329.6 million in Q4 2023 [11][12] - Adjusted net income for Q4 2024 was 24.7million,upfrom14.3 million in Q4 2023, with adjusted diluted earnings per share of 0.15comparedto0.09 in the prior year [13][11] Cost and Expense Management - Total cost of revenue for Q4 2024 was 38.3million,anincreasefrom34.1 million in Q4 2023, mainly due to higher employee-related expenses and software amortization [9][8] - Total operating expenses decreased to 56.1millionfrom62.4 million in Q4 2023, primarily due to a reduction in the change in fair value of contingent consideration [10][8] 2025 Financial Outlook - Certara expects full-year 2025 revenue to be in the range of 415millionto425 million [16] - The company anticipates adjusted EBITDA margins to remain in the low thirties for 2025 [3][16] - Adjusted diluted earnings per share for 2025 is projected to be between 0.42and0.46 [16]